{"id":41390,"date":"2025-11-07T14:00:00","date_gmt":"2025-11-07T14:00:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4817363_HK17363_0"},"modified":"2025-11-07T14:00:00","modified_gmt":"2025-11-07T14:00:00","slug":"hanchorbio-presents-two-late-breaking-abstracts-at-the-society-for-immunotherapy-of-cancer-2025-demonstrating-best-in-class-potential-of-hcb101-in-advanced-cancers","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=41390","title":{"rendered":"HanchorBio Presents Two Late-Breaking Abstracts at the Society for Immunotherapy of Cancer 2025 Demonstrating Best-in-Class Potential of HCB101 in Advanced Cancers"},"content":{"rendered":"
\n

Late-breaking poster presentations show HCB101’s favorable safety, strong receptor occupancy, and promising monotherapy and combination activity in tumors historically unresponsive to immunotherapy<\/i><\/p>\n

TAIPEI<\/span>, SHANGHAI<\/span>, and SAN FRANCISCO<\/span><\/span>, Nov. 7, 2025<\/span><\/span> \/PRNewswire\/ — HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced the presentation of two late-breaking abstracts on its lead asset, HCB101, at the 40th <\/sup>Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held November 5-9, 2025<\/span>, in National Harbor, Maryland<\/span>. Both datasets were accepted for late-breaking poster presentations, highlighting the program’s potential impact on innate immune checkpoint blockade.<\/p>\n

\n

\"HCB101,<\/a>
HCB101, a Next-Generation Fc-Engineered SIRP\u03b1-CD47 Fusion Protein, Demonstrates Favorable Safety and Early Antitumor Activity in Advanced Cancers<\/span><\/p>\n<\/p><\/div>\n

HCB101’s progress reflects its distinct engineering compared to earlier CD47-targeting approaches. First-generation CD47 antibodies, such as magrolimab and lemzoparlimab, demonstrated clinical activity but faced significant safety or efficacy challenges, leading to discontinuations or halted collaborations. Second-generation wild-type SIRP\u03b1 fusions, such as maplirpacept (TTI-622), improved safety but did not deliver sufficient efficacy in solid tumors, limiting their adoption. IgG1-based fusions attempted to boost immune activation but triggered excessive Fc\u03b3-mediated toxicity and poor tolerability, restricting their use mainly to hematologic malignancies. Third-generation engineered SIRP\u03b1 fusions with inactivated IgG1 Fc improved safety in combinations but showed limited standalone efficacy. <\/p>\n

“The acceptance of two late-breaking abstracts at SITC for HCB101 monotherapy and combination therapy, along with our earlier preclinical abstract for HCB301, a tri-specific fusion targeting SIRP\u03b1\/CD47, PD-1\/PD-L1, and TGF\u03b2, reinforces the scientific breadth of our platform across innate and adaptive immunity,” said Scott Liu<\/span>, Ph.D., Founder, Chairman, and CEO of HanchorBio. <\/b>“HCB101 was purposely engineered to overcome the cytopenias seen with first-generation anti-CD47 antibodies while maintaining potent immune activation. In second-line gastric cancer, the combination of HCB101 with standard-of-care therapy achieved a 100% confirmed response rate in the active-dose cohort, far exceeding the 28% ORR benchmark from the RAINBOW trial. These results position HCB101 not just as a safer SIRP\u03b1-CD47 backbone, but as a next-generation macrophage checkpoint immunotherapy with best-in-class potential.”<\/p>\n

Late-Breaking Abstract Highlights (Data as of August 2025<\/span>)<\/p>\n

1. HCB101-101 Monotherapy Study (NCT05892718)<\/p>\n

Title: HCB101, a Next-Generation Fc-Engineered SIRP\u03b1-CD47 Fusion Protein, <\/i><\/b>Demonstrates Favorable Safety and Early Antitumor Activity in Advanced Cancers<\/i><\/b><\/p>\n